These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 34903604)
1. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk. Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604 [TBL] [Abstract][Full Text] [Related]
2. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk. Stolarova L; Kleiblova P; Zemankova P; Stastna B; Janatova M; Soukupova J; Achatz MI; Ambrosone C; Apostolou P; Arun BK; Auer P; Barnard M; Bertelsen B; ; Blok MJ; Boddicker N; Brunet J; Burnside ES; Calvello M; Campbell I; Chan SH; Chen F; Chiang JB; Coppa A; Cortesi L; Crujeiras-González A; ; De Leeneer K; De Putter R; DePersia A; Devereux L; Domchek S; Efremidis A; Engel C; Ernst C; Evans DGR; Feliubadaló L; Fostira F; Fuentes-Ríos O; Gómez-García EB; González S; Haiman C; Hansen TVO; Hauke J; Hodge J; Hu C; Huang H; Ishak NDB; Iwasaki Y; Konstantopoulou I; Kraft P; Lacey J; Lázaro C; Li N; Lim WK; Lindstrom S; Lori A; Martinez E; Martins A; Matsuda K; Matullo G; McInerny S; Michailidou K; Montagna M; Monteiro ANA; Mori L; Nathanson K; Neuhausen SL; Nevanlinna H; Olson JE; Palmer J; Pasini B; Patel A; Piane M; Poppe B; Radice P; Renieri A; Resta N; Richardson ME; Rosseel T; Ruddy KJ; Santamariña M; Dos Santos ES; Teras L; Toland AE; Trentham-Dietz A; Vachon CM; Volk AE; Weber-Lassalle N; Weitzel JN; Wiesmuller L; Winham S; Yadav S; Yannoukakos D; Yao S; Zampiga V; Zethoven M; Zhang ZW; Zima T; Spurdle AB; Vega A; Rossing M; Del Valle J; De Nicolo A; Hahnen E; Claes KBM; Ngeow J; Momozawa Y; James PA; Couch FJ; Macurek L; Kleibl Z Clin Cancer Res; 2023 Aug; 29(16):3037-3050. PubMed ID: 37449874 [TBL] [Abstract][Full Text] [Related]
3. CHEK2 variants: linking functional impact to cancer risk. Boonen RACM; Vreeswijk MPG; van Attikum H Trends Cancer; 2022 Sep; 8(9):759-770. PubMed ID: 35643632 [TBL] [Abstract][Full Text] [Related]
4. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance. Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080 [TBL] [Abstract][Full Text] [Related]
5. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813 [TBL] [Abstract][Full Text] [Related]
6. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692 [TBL] [Abstract][Full Text] [Related]
8. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants. Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337 [TBL] [Abstract][Full Text] [Related]
9. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951 [TBL] [Abstract][Full Text] [Related]
10. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994 [TBL] [Abstract][Full Text] [Related]
11. The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients. Wagener R; Walter C; Auer F; Alzoubi D; Hauer J; Fischer U; Varghese J; Dugas M; Borkhardt A; Brozou T Int J Cancer; 2023 Apr; 152(7):1388-1398. PubMed ID: 36468172 [TBL] [Abstract][Full Text] [Related]
13. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin. Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236 [TBL] [Abstract][Full Text] [Related]
15. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
16. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk. Wang N; Ding H; Liu C; Li X; Wei L; Yu J; Liu M; Ying M; Gao W; Jiang H; Wang Y Oncogene; 2015 Oct; 34(40):5198-205. PubMed ID: 25619829 [TBL] [Abstract][Full Text] [Related]
17. Rare, protein-truncating variants in Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002 [TBL] [Abstract][Full Text] [Related]
18. Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Roeb W; Higgins J; King MC Hum Mol Genet; 2012 Jun; 21(12):2738-44. PubMed ID: 22419737 [TBL] [Abstract][Full Text] [Related]
19. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Sodha N; Bullock S; Taylor R; Mitchell G; Guertl-Lackner B; Williams RD; Bevan S; Bishop K; McGuire S; Houlston RS; Eeles RA Br J Cancer; 2002 Dec; 87(12):1445-8. PubMed ID: 12454775 [TBL] [Abstract][Full Text] [Related]
20. Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas. De Sousa SMC; McCormack A; Orsmond A; Shen A; Yates CJ; Clifton-Bligh R; Santoreneos S; King J; Feng J; Toubia J; Torpy DJ; Scott HS J Clin Endocrinol Metab; 2024 Oct; 109(11):2720-2728. PubMed ID: 38651569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]